Status:
COMPLETED
Transanal Total Mesorectal Excision Versus Laparoscopic TME for Rectal Cancer
Lead Sponsor:
Third Military Medical University
Conditions:
Rectal Neoplasms
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
To investigates the feasibility, practicability, safety and subjective as well as functional outcome of transanal minimal invasive surgery toal mesentery excision for rectal cancer.
Detailed Description
Natural orifice transluminal endoscopic surgery (NOTES) give the opportunity to reduce surgical access trauma leading to a more painless surgery and enhancing a fast postoperative recovery. Experience...
Eligibility Criteria
Inclusion
- Biopsy-proven adenocarcinoma of the rectum
- Eligible to undergo conventional laparoscopic low anterior resection or transanal hybrid-laparoscopic low anterior resection with or without a temporary diverting stoma
- Node negative (N0), T1 (high risk features), T2 and T3 rectal cancer on pelvic MRI
- Closest distance between tumor edge and mesorectal fascia 5mm or more based on pelvic MRI
- Rectal cancer located 3-10 cm from the anal verge
Exclusion
- Metastasis
- Obstructing rectal cancer
- Synchronous colon cancer
- T4 rectal cancer not treated preoperatively with full-course chemoradiation
- Pregnant or breast-feeding
- Receiving any other study agents
- Fecal incontinence
- History of prior colorectal cancer
- History of inflammatory bowel disease
- History of pelvic radiation
- BMI \> 40
- Large uterine fibroids
- Uncontrolled intercurrent illness
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2020
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT02252250
Start Date
October 1 2014
End Date
November 1 2020
Last Update
November 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Daping hospital
Chongqing, Chongqing Municipality, China, 400042